Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LOU064 in inadequately controlled asthma
2018-003609-24Phase 2Terminated
- Sponsor
- Novartis
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in asthma comparing LOU064 with Placebo (2 arms). Primary endpoint: Change from baseline in pre-dose FEV1 at Week 12. Started Jul 2019; status: terminated.
02
Drugs
remibrutinib
03
Conditions
asthma
Beyond the preview
Go deeper on 2018-003609-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003609-24.